Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Phase 1, Double-blind, Placebo-controlled Crossover Study of SAGE-718 Using a Ketamine Challenge, to Evaluate the Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

To see complete record on, please visit this link

Id: NCT03771586

Organisation Name: Sage Therapeutics

Overal Status: Completed

Start Date: September 24, 2018

Last Update: January 31, 2022

Lead Sponsor: Sage Therapeutics

Brief Summary: This study is a phase 1, double-blind, placebo-controlled crossover study of single, oral dose of SAGE-718 using a ketamine challenge, to evaluate the electrophysiology, safety, tolerability, and pharmacokinetics in healthy subjects

  • Healthy Volunteer

Total execution time in seconds: 0.3558030128479